TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18027183

Group type: EXPERIMENTAL
Intervention: Ethylcellulose inserts of niridazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15999036

Group type: EXPERIMENTAL
Intervention: Autotransfusion (washed salvaged red blood cells)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (homologous blood only)
Number of subjects: 61
Study: 12432291

Group type: EXPERIMENTAL
Intervention: Internal sphincterotomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: No internal sphincterotomy
Number of subjects: 42
Study: 10673919

Group type: EXPERIMENTAL
Intervention: Adhesive film dressing covering the nipple-areolar complex
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no shields)
Number of subjects: 25
Study: 8942462

Group type: EXPERIMENTAL
Intervention: Fluoxetine augmentation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 1887483

Group type: EXPERIMENTAL
Intervention: Albendazole 15 mg/kg/d for 30 d
Number of subjects: 100

Group type: COMPARATOR
Intervention: Praziquantel 50 mg/kg/d for 15 d
Number of subjects: 100
Study: 6138064

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Midazolam 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31698695

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich mixed berry smoothie (400 mL) containing equal amounts of blueberry, strawberry, raspberry, and blackberry, n = 20
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched placebo smoothie, n = 20
Number of subjects: 40
Study: 30394200

Group type: EXPERIMENTAL
Intervention: Difficult access to healthcare (problems with distance/travel cost, history of moving residence in the past year)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Lack of TB knowledge (lack of knowledge about TB transmission, cause of TB, unawareness of consequences of stopping treatment)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Treatment experience (lack of TB education provided by TB nurse, use of loose vs. fixed-dose combinations)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Being aged under 35 years
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Having a history of TB in the family
Number of subjects: 264
Study: 27173807

Group type: EXPERIMENTAL
Intervention: Living Well with Asthma website access for minimum 12 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study: 24534073

Group type: EXPERIMENTAL
Intervention: Total bilirubin levels >8 and ≤10 μmol/L
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Total bilirubin levels >10 and ≤13 μmol/L
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Total bilirubin levels >13 μmol/L
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Total bilirubin levels ≤8 μmol/L
Number of subjects: 10000
Study: 22878452

Group type: EXPERIMENTAL
Intervention: Topical administration of sodium hyaluronate and diquafosol tetrasodium
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sodium hyaluronate monotherapy
Number of subjects: 32
Study: 20650358

Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 1518
Study: 17379049

Group type: EXPERIMENTAL
Intervention: Fixed combination of cinnarizine 20 mg + dimenhydrinate 40 mg
Number of subjects: 246

Group type: COMPARATOR
Intervention: Cinnarizine 50 mg
Number of subjects: 246

Group type: COMPARATOR
Intervention: Dimenhydrinate 100 mg
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 15733880

Group type: EXPERIMENTAL
Intervention: Exercise program (3 times a week for 12 weeks)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study: 12019378

Group type: EXPERIMENTAL
Intervention: Insulin-enhanced cardioplegia (10 IU/L insulin)
Number of subjects: 1127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1127
Study: 10219332

Group type: EXPERIMENTAL
Intervention: Early administration of filgrastim (5 micrograms/kg) starting +1 day postchemotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Delayed administration of filgrastim (5 micrograms/kg) starting +5 days postchemotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Early administration of filgrastim
Number of subjects: 18

Group type: COMPARATOR
Intervention: Delayed administration of filgrastim
Number of subjects: 18
Study: 10150846

Group type: EXPERIMENTAL
Intervention: Collagen shields
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subconjunctival injection
Number of subjects: 0
Study: 2163450

Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lisinopril, 10 mg once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study: 661731

Group type: EXPERIMENTAL
Intervention: 6 mg highly purified dextrothyroxine for 12 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 900 mg beta‐pyridylcarbinol for 12 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of 4 mg dextrothyroxine and 600 mg beta‐pyridylcarbinol daily for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Monotherapy with dextrothyroxine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Monotherapy with beta‐pyridylcarbinol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined treatment of dextrothyroxine and beta‐pyridylcarbinol
Number of subjects: 22
Study: 30063556

Group type: EXPERIMENTAL
Intervention: Low-Intensity Resistance Training with Partial Vascular Occlusion (LI-BFR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-Intensity Resistance Training (HI-RT)
Number of subjects: 28
Study: 29402870

Group type: EXPERIMENTAL
Intervention: Mentalization-Based Treatment (MBT) in combination with SUD treatment, n = 24
Number of subjects: 46

Group type: COMPARATOR
Intervention: SUD treatment alone, n = 22
Number of subjects: 46
Study: 27393009

Group type: EXPERIMENTAL
Intervention: Sprifermin (100 μg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 24717363

Group type: COMPARATOR
Intervention: Refined wheat bread (RWB)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Refined rye bread (RRB)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Whole‐meal rye bread (WRB)
Number of subjects: 19
Study: 22585389

Group type: EXPERIMENTAL
Intervention: Successful metaphorical story
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsuccessful metaphorical story
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmetaphorical expression
Number of subjects: 0
Study: 20843313

Group type: EXPERIMENTAL
Intervention: Early detection and counselling intervention (personal advice to parents to prevent smoke exposure, referral to general practitioner or asthma nurse)
Number of subjects: 7893

Group type: EXPERIMENTAL
Intervention: Early detection and counselling intervention
Number of subjects: 7893

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 7893
Study: 18172067

Group type: EXPERIMENTAL
Intervention: First-eye cataract surgery
Number of subjects: 306
Study: 15892532

Group type: EXPERIMENTAL
Intervention: Sealants with a bonding agent
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sealants without a bonding agent
Number of subjects: 30
Study: 12510039

Group type: COMPARATOR
Intervention: Two infusions of 6 mg of natalizumab per kilogram
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Two infusions of 3 mg of natalizumab per kilogram
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: All natalizumab groups
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Groups receiving two infusions of natalizumab
Number of subjects: 248

Group type: COMPARATOR
Intervention: All four groups
Number of subjects: 248
Study: 10394423

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 52
Study: 8834062

Group type: EXPERIMENTAL
Intervention: Low-intensity anticoagulation (e.g., warfarin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anticoagulation management systems
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: INR level management
Number of subjects: 100
Study: 1829981

Group type: EXPERIMENTAL
Intervention: Metoprolol (1 x 100 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cilazapril (1 x 2.5 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 6410908

Group type: EXPERIMENTAL
Intervention: methylprednisolone 80 mg intravenously plus Vivonex‐HN, 2 L/day po
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: methylprednisolone 80 mg intravenously plus total parenteral nutrition, 2.5 L/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: total parenteral nutrition, 2.5 L/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vivonex‐HN, 2 L/day po
Number of subjects: 24
Study: 30910388

Group type: EXPERIMENTAL
Intervention: Rhythm control (maintenance of sinus rhythm by catheter ablation and/or antiarrhythmic drugs)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Rhythm control (maintenance of sinus rhythm)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 283
Study: 29527702

Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil once a day for 6 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (oral multivitamin tablet) once a day for 6 weeks
Number of subjects: 100
Study: 27630326

Group type: EXPERIMENTAL
Intervention: Fluorouracil, epirubicin and cyclophosphamide followed by docetaxel
Number of subjects: 3754

Group type: COMPARATOR
Intervention: FEC followed by docetaxel plus gemcitabine
Number of subjects: 3754

Group type: EXPERIMENTAL
Intervention: 2 vs. 5 years of treatment with zoledronic acid
Number of subjects: 3754

Group type: EXPERIMENTAL
Intervention: CA27.29 and CTC positivity association
Number of subjects: 3754
Study: 24290600

Group type: EXPERIMENTAL
Intervention: Moderately restricted carbohydrate (MRC) diet
Number of subjects: 30
Study: 22359079

Group type: EXPERIMENTAL
Intervention: Designed slippers splints
Number of subjects: 30

Group type: COMPARATOR
Intervention: Market splints (including night splints and interdigital pads)
Number of subjects: 30
Study: 20054553

Group type: EXPERIMENTAL
Intervention: Epirubicin 20 mg/40 ml saline
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Epirubicin 50 mg/100 ml
Number of subjects: 303

Group type: COMPARATOR
Intervention: TUR alone (Control)
Number of subjects: 303
Study: 18270335

Group type: EXPERIMENTAL
Intervention: letrozole
Number of subjects: 5170

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5170
Study: 16708818

Group type: EXPERIMENTAL
Intervention: Combination of Jianweiyuyang granules and ranitidine capsules
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Jianweiyuyang granules
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ranitidine capsules
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no peptic ulcers)
Number of subjects: 120
Study: 12843349

Group type: EXPERIMENTAL
Intervention: BFV measurements using the new ultrasonic device
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Total BFV value obtained from both ICAs
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: BFV value of 220 mL/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: BFV sensitivity and specificity for hyperemic range
Number of subjects: 23
Study: 11063163

Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sedation with intravenous saline (placebo group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No intravenous cannula (control group)
Number of subjects: 180
Study: 9305489

Group type: EXPERIMENTAL
Intervention: Cisapride 60 mg (2 x 30 mg suppositories)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8327649

Group type: EXPERIMENTAL
Intervention: Instituto Butantan antivenom
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Instituto Vital Brazil antivenom
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: FUNED antivenom
Number of subjects: 121

Group type: COMPARATOR
Intervention: All three antivenoms
Number of subjects: 121
Study: 3555063

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily
Number of subjects: 3981

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg twice daily
Number of subjects: 3981

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 3981
Study: 29621048

Group type: EXPERIMENTAL
Intervention: Tongue pressure strength and accuracy training (TPSAT) with traditional dysphagia therapy for 30 minutes each per day, 5 times per week for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional dysphagia therapy for 30 minutes twice a day, 5 times per week for 8 weeks
Number of subjects: 16
Study: 28237859

Group type: EXPERIMENTAL
Intervention: Standard of care plus monthly lifestyle group education sessions of 45min duration
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 223
Study: 26174128

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 400 μg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23292558

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mouth rinse (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) treatment
Number of subjects: 0
Study: 21631568

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day (CX2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study: 18053781

Group type: EXPERIMENTAL
Intervention: Ilio-inguinal nerve block with ropivicaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Wound irrigation with ropivicaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline (control for ilio-inguinal nerve block)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline (control for wound irrigation)
Number of subjects: 12
Study: 16602577

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 95
Study: 13677263

Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by stem-cell rescue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tandem transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon-alpha and glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalidomide and immunomodulatory derivatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 10709881

Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acids in mothers' milk
Number of subjects: 19
Study: 9092744

Group type: EXPERIMENTAL
Intervention: Psoralen-UVB treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional psoralen-UVA treatment
Number of subjects: 100
Study: 8458681

Group type: EXPERIMENTAL
Intervention: SQ29,852 (mean dose 15.0 ± 5.1 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Atenolol (mean dose 37.5 ± 18.5 mg/day)
Number of subjects: 46
Study: 31785056

Group type: EXPERIMENTAL
Intervention: Prostaglandin (PG) inpatient group (Dinoprostone, either 2 mg gel or 10 mg controlled-release tape)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Balloon outpatient group (double-balloon catheter inserted and went home)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Balloon outpatient group
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Prostaglandin (PG) inpatient group
Number of subjects: 695
Study: 31045422

Group type: EXPERIMENTAL
Intervention: LEAF intervention (N = 86)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Emotion reporting/waitlist control (N = 84)
Number of subjects: 170
Study: 28926528

Group type: EXPERIMENTAL
Intervention: Community symptom awareness campaign tailored for rural Australians
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: GP intervention: resource card with symptom risk assessment charts and local cancer referral pathways
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Community campaign control region
Number of subjects: 1358

Group type: COMPARATOR
Intervention: GP control
Number of subjects: 1358
Study: 27230616

Group type: EXPERIMENTAL
Intervention: Custom-made serially adjustable rigid wrist/hand orthoses (WHO), prescribed for 6 hours nightly (or daily) for 3 years.
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual multidisciplinary care (control group).
Number of subjects: 194
Study: 24387929

Group type: EXPERIMENTAL
Intervention: Bladder neck sling suspension technique
Number of subjects: 57
Study: 22588639

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS applied to the contralesional M1 for 30 minutes before motor training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS for 30 minutes before motor training
Number of subjects: 40
Study: 20402874

Group type: EXPERIMENTAL
Intervention: suxamethonium 1.5 mg.kg(‐1) (Group S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rocuronium 1 mg.kg(‐1) (Group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: suxamethonium 1.5 mg.kg(‐1) (Group SO)
Number of subjects: 60
Study: 17379588

Group type: EXPERIMENTAL
Intervention: Granulocytapheresis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 40
Study: 15668474

Group type: EXPERIMENTAL
Intervention: Oophorectomy and tamoxifen treatment for breast cancer
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 682

Group type: COMPARATOR
Intervention: Parity and age at first birth
Number of subjects: 682

Group type: COMPARATOR
Intervention: Family history, age at menarche, cumulative lactation, body mass index, education
Number of subjects: 682
Study: 12042545

Group type: EXPERIMENTAL
Intervention: Community nurse (home visit) follow-up
Number of subjects: 586

Group type: COMPARATOR
Intervention: Hospital nurse (clinic) follow-up
Number of subjects: 586
Study: 9709910

Group type: EXPERIMENTAL
Intervention: CDS-A pattern (intraparenchymal homogeneous vascular color spots)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CDS-B pattern (vascular bands with avascular areas)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mixed pattern (A-B pattern)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Normal TRAb levels
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CDS patterns
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Histological findings
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Velocity of systolic peak (VP)
Number of subjects: 16
Study: 7874900

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound measurements after blood donation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Baseline measurements before hemorrhage
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Measurements 24 hours after hemorrhage
Number of subjects: 7
Study: 2147043

Group type: EXPERIMENTAL
Intervention: Dacron graft with collagen coating
Number of subjects: 128

Group type: COMPARATOR
Intervention: Dacron graft (non-collagen coated)
Number of subjects: 128
Study: 152180

Group type: EXPERIMENTAL
Intervention: Iocetamic acid (Cholebrin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium ipodate (Solubiloptin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both contrast media
Number of subjects: 50
Study: 31624988

Group type: EXPERIMENTAL
Intervention: Symfony ZXR00
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ZLB00
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: SV25T0
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ATLISA 809M, ATLISA Tri 839MP, ZLB00
Number of subjects: 115
Study: 30187221

Group type: EXPERIMENTAL
Intervention: Immunonutrition supplements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard polymeric supplements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nutrition supplements (both types)
Number of subjects: 20
Study: 30256102

Group type: EXPERIMENTAL
Intervention: Single water treatment interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single water treatment and handwashing interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined WSH interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions (WSH improvements)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water treatment and handwashing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined interventions
Number of subjects: 0
Study: 27610423

Group type: EXPERIMENTAL
Intervention: Standard of care plus iChoose Kidney
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard of care (usual transplantation education)
Number of subjects: 450
Study: 24192062

Group type: EXPERIMENTAL
Intervention: Combination of leukotriene receptor antagonist (LRA), H1 antihistamine, and H2 antihistamine (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group continued with previously taken two combination regimens (Group B)
Number of subjects: 50
Study: 22648629

Group type: EXPERIMENTAL
Intervention: Psyllium fibre added to extruded snack products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oat bran inclusion in extruded snack products
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control snack product recipe
Number of subjects: 0
Study: 19156564

Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral cue words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative cue words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical arousal during memory retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17618330

Group type: EXPERIMENTAL
Intervention: Systemic metronidazole and amoxicillin (500 mg amoxicillin + 250 mg metronidazole every eight hours for seven days) with scaling and root planing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo with scaling and root planing
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Systemic metronidazole and amoxicillin with scaling and root planing
Number of subjects: 50